845305-86-4

Basic information

• Product Name: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE
• Synonyms: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE;5-broMo-N,N-diMethylpicolinaMide;5-BroMo-N,N-diMethylpyridine-2-carboxaMide, 96%
• CAS NO: 845305-86-4
• Molecular Formula: C₈H₉BrN₂O
• Molecular Weight: 229.07
• Mol File: 845305-86-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE(845305-86-4)
• EPA Substance Registry System: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE(845305-86-4)

Safety Data

• Hazardous Substances Data: 845305-86-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemical Synthesis:
5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE is used as an organic chemical synthesis intermediate for the production of various pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structure allows it to serve as a building block or a key component in the synthesis of complex organic molecules, facilitating the development of new compounds with potential applications in various industries.

Upstream product

• 30766-11-1 5-bromoisonicotinic acid 
• 124-40-3 dimethyl amine 
• 506-59-2 N,N-dimethylammonium chloride 
• 137178-88-2 5-bromopyridine-2-carbonyl chloride 
• 97483-77-7 2-Cyano-5-bromopyridine 

Downstream Products

• 1020855-13-3 N,N-dimethyl-5-[3-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-5-[(5-methylpyrazin-2-yl)carbamoyl]phenoxy]pyridine-2-carboxamide 
• 1006876-27-2 N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carboxamide 
• 1433497-55-2 methyl 4-[3-(3,5-di-tert-butylphenyl)-2-[6-(dimethylcarbamoyl)-3-pyridyl]-3,4-dihydropyrazol-5-yl]benzoate 

Relevant articles and documents

N2-carbamylaryl-2-aminopyrimidine derivative and medical application thereof

The invention provides an N2-carbamylaryl-2-aminopyrimidine derivative and a medical application thereof. The N2-carbamylaryl-2-aminopyrimidine derivative provided by the invention comprises an optical isomer of the N2-carbamylaryl-2-aminopyrimidine derivative and pharmaceutically acceptable salt thereof. Pharmacodynamic research shows that the traditional Chinese medicine composition has no toxicor side effect, the compound has an FLT3 inhibitory activity. The proliferation inhibition activity is realized on various leukemia cell strains; a medium inhibition effect is achieved on breast cancer cells; moreover, the polypeptide is effective for multiple mutations of AML, such as internal tandem repeat mutation of a near-membrane structural domain and D835 point mutation of an activated ring in a kinase structural domain, almost has no inhibition effect on c-KIT, can overcome drug resistance brought by clinical point mutation, can reduce toxic and side effects of bone marrow inhibition,and can be applied to preparation of antitumor drugs. The structures of the general formulas Ia and Ib of the N2-carbamylaryl-2-aminopyrimidine derivative are shown in the specification,

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.

TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.

9H-PYRROLO-DIPYRIDINE DERIVATIVES

The invention relates to 9H-pyrrolo-dipyridine derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection of Tau aggregates.

SUBSTITUTED PYRAZOLE ANALOGUES AS RAR ANTAGONISTS

The present invention provides compounds of Formula I or a pharmaceutical salt thereof; methods of treating osteoarthritis and the pain associated with osteoarthritis using the compounds; and processes for preparing the compounds.

SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1

The present invention relates to certain spirocyclic compounds that are inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 (11βHSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other di

SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel piperidine ether derivatives having affinity for the histamine H3 receptor, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.